Matinas Biopharma Hl (MTNB) 0.6300 $MTNB
Matinas BioPharma Reports 2015 Financial Results and Provides Business Update
GlobeNewswire - Thu Mar 31, 6:05AM CDT
-- 2015 transformative year with focus on developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections
UPDATE -- OTCQX and OTCQB Companies to Present at 2016 Roth Conference
PR Newswire - Mon Mar 14, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 4.81 (+0.06), CDXC: 5.76 (+0.20)
Matinas BioPharma to Present at the 28th Annual ROTH Conference
GlobeNewswire - Thu Mar 10, 6:35AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, announced today that it will present at the 28 Annual ROTH Conference on Tuesday, March 15, 2016 at 5:00 p.m. PT in Dana Point, CA.
OTCQX And OTCQB Companies To Present At 2016 ROTH Conference
PR Newswire - Thu Mar 10, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 4.81 (+0.06), CDXC: 5.76 (+0.20)
A Potential Answer To Antibiotic Resistance
ACCESSWIRE - Mon Mar 07, 12:22PM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / In a report modeled by Rand Europe and KPMG, and presented to the UK government at the end of 2014, analysts expect that by 2050, superbugs will kill more patients globally than cancer. Not something that is currently in the public consciousness, but a terrifying statistic nonetheless.
JNJ: 114.76 (+0.27), CMRX: 4.78 (-0.21), MRK: 56.64 (-0.18), CDTX: 11.27 (+0.07), GSK: 42.89 (+0.48)
Matinas BioPharma Granted U.S. Orphan Drug Designation for MAT2501 for Treatment of Non-Tuberculous Mycobacteria Infections
GlobeNewswire - Mon Mar 07, 6:05AM CST
- MAT2501 (encochleated amikacin) previously designated a Qualified Infectious Disease Product by FDA -
Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
GlobeNewswire - Wed Feb 10, 7:05AM CST
- Patent Includes Pharmaceutical Use Claims for Lead Anti-Infective Product Candidates MAT2203 (Encochleated Amphotericin
and MAT2501 (Encochleated Amikacin) -
Matinas BioPharma to Present at Biotech Showcase(TM) on January 12, 2016
GlobeNewswire - Tue Jan 05, 6:01AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, announced today that it will present at the 8th Annual Biotech Showcase(TM) conference on Tuesday, January 12, 2016 at 2:30 p.m. PT in San Francisco, CA.
Matinas BioPharma Files Investigational New Drug Application With U.S. FDA for Lead Antibacterial Development Candidate MAT2501
GlobeNewswire - Mon Jan 04, 6:05AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, announced today that on December 31, 2015, the Company filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its lead antibacterial development candidate, MAT2501.
Matinas BioPharma Holdings, Inc. - MTNB Transforms The World of Anti-Infectives: Oral Delivery Beats Injection
ACCESSWIRE - Wed Dec 23, 7:47AM CST
NEW YORK, NY / ACCESSWIRE / December 23, 2015 / Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) today published a series of blog posts on The Chairman's Blog, written by the Company's Chief Executive Officer, Dr. Roelof Rongen and Chief Technology Officer, Dr. Raphael Mannino. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Treatment of Aspergillus by U.S. FDA
GlobeNewswire - Thu Dec 17, 6:05AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead drug candidate MAT2203 as a Qualified Infectious Disease Product (QIDP) with Fast Track status for the treatment of aspergillus.
Matinas BioPharma to Present at the 8th Annual LD Micro Main Event on December 3, 2015
GlobeNewswire - Thu Nov 19, 6:05AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it will present at the 8 Annual LD Micro Main Event on December 3, 2015, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) at the Luxe Sunset Hotel in Los Angeles, CA.
Matinas BioPharma Reports 2015 Third Quarter Financial Results and Provides Business Update
GlobeNewswire - Tue Nov 10, 6:35AM CST
- Topline data from Phase 2a clinical trial with MAT2203, oral encochleated amphotericin B, expected in 2016 -
Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Encochleated siRNA
GlobeNewswire - Mon Oct 26, 7:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO"
for U.S. Patent Application Serial No. 14/038,810 entitled, "Cochleate Compositions Directed Against Expression of Proteins."
Matinas BioPharma Selected to Present at Cavendish Global Health Impact Forum
GlobeNewswire - Thu Oct 22, 7:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it has been selected as a Cavendish Innovation Partner and will present at the Cavendish Global Health Impact Forum co-hosted by The Cleveland Clinic, which takes place October 25 to October 28 at The Cleveland Clinic, Cleveland, Ohio.
Matinas BioPharma to Present at the 14th Annual BIO Investor Forum on October 20, 2015
GlobeNewswire - Wed Oct 14, 6:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it will be presenting at the 14 Annual BIO Investor Forum being held October 20-21, 2015, at the Parc 55 in San Francisco, California.
Matinas BioPharma Presents Preclinical PK and Efficacy Data of Encochleated Atovaquone in Murine Model at IDWeek 2015
GlobeNewswire - Sat Oct 10, 7:00AM CDT
- CATQ - Encochleated Atovaquone - Demonstrates Enhanced Efficacy and Tissue Targeting over Current Formulation -
MarketExclusive.com - Maxim Group Reiterates BUY Rating for Matinas BioPharma Holdings, Inc. and Provides Company Update
ACCESSWIRE - Mon Oct 05, 1:04PM CDT
NEW YORK, NY / ACCESSWIRE / October 5, 2015 / Market Exclusive announces that Maxim Group has reiterated a Buy rating for Matinas BioPharma Holdings, Inc. (OTCQB:MTNB) with a 12-month price target of $6.00 per share. The analyst note was published following the announcement that Matinas has received IRB approval to commence a NIH-Sponsored Phase 2a study with MAT2203.
Matinas BioPharma Receives Institutional Review Board Approval to Commence NIH-Sponsored Phase 2a Study With MAT2203 - An Orally Delivered, Encochleated Formulation of Amphotericin B -
GlobeNewswire - Mon Oct 05, 6:00AM CDT
- NIH IRB Approves Study of MAT2203 - Oral, Encochleated Formulation of Amphotericin B -
Matinas BioPharma Presents Pre-clinical Data Showing Anti-bacterial Activity of MAT2501 - Encochleated Amikacin - Against Mycobacterium Avium Lung Infections at ICAAC/ICC 2015
GlobeNewswire - Sat Sep 19, 1:00PM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today presented preclinical data showing significant anti-bacterial activity against Mycobacterium avium (M. avium) and no noted toxicity by MAT2501, an orally-administered encochleated formulation of amikacin.
Matinas BioPharma Reports 2015 Financial Results and Provides Business Update
GlobeNewswire - Thu Mar 31, 6:05AM CDT
-- 2015 transformative year with focus on developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections
UPDATE -- OTCQX and OTCQB Companies to Present at 2016 Roth Conference
PR Newswire - Mon Mar 14, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 4.81 (+0.06), CDXC: 5.76 (+0.20)
Matinas BioPharma to Present at the 28th Annual ROTH Conference
GlobeNewswire - Thu Mar 10, 6:35AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, announced today that it will present at the 28 Annual ROTH Conference on Tuesday, March 15, 2016 at 5:00 p.m. PT in Dana Point, CA.
OTCQX And OTCQB Companies To Present At 2016 ROTH Conference
PR Newswire - Thu Mar 10, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 4.81 (+0.06), CDXC: 5.76 (+0.20)
A Potential Answer To Antibiotic Resistance
ACCESSWIRE - Mon Mar 07, 12:22PM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / In a report modeled by Rand Europe and KPMG, and presented to the UK government at the end of 2014, analysts expect that by 2050, superbugs will kill more patients globally than cancer. Not something that is currently in the public consciousness, but a terrifying statistic nonetheless.
JNJ: 114.76 (+0.27), CMRX: 4.78 (-0.21), MRK: 56.64 (-0.18), CDTX: 11.27 (+0.07), GSK: 42.89 (+0.48)
Matinas BioPharma Granted U.S. Orphan Drug Designation for MAT2501 for Treatment of Non-Tuberculous Mycobacteria Infections
GlobeNewswire - Mon Mar 07, 6:05AM CST
- MAT2501 (encochleated amikacin) previously designated a Qualified Infectious Disease Product by FDA -
Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
GlobeNewswire - Wed Feb 10, 7:05AM CST
- Patent Includes Pharmaceutical Use Claims for Lead Anti-Infective Product Candidates MAT2203 (Encochleated Amphotericin
and MAT2501 (Encochleated Amikacin) - Matinas BioPharma to Present at Biotech Showcase(TM) on January 12, 2016
GlobeNewswire - Tue Jan 05, 6:01AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, announced today that it will present at the 8th Annual Biotech Showcase(TM) conference on Tuesday, January 12, 2016 at 2:30 p.m. PT in San Francisco, CA.
Matinas BioPharma Files Investigational New Drug Application With U.S. FDA for Lead Antibacterial Development Candidate MAT2501
GlobeNewswire - Mon Jan 04, 6:05AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, announced today that on December 31, 2015, the Company filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its lead antibacterial development candidate, MAT2501.
Matinas BioPharma Holdings, Inc. - MTNB Transforms The World of Anti-Infectives: Oral Delivery Beats Injection
ACCESSWIRE - Wed Dec 23, 7:47AM CST
NEW YORK, NY / ACCESSWIRE / December 23, 2015 / Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) today published a series of blog posts on The Chairman's Blog, written by the Company's Chief Executive Officer, Dr. Roelof Rongen and Chief Technology Officer, Dr. Raphael Mannino. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Treatment of Aspergillus by U.S. FDA
GlobeNewswire - Thu Dec 17, 6:05AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead drug candidate MAT2203 as a Qualified Infectious Disease Product (QIDP) with Fast Track status for the treatment of aspergillus.
Matinas BioPharma to Present at the 8th Annual LD Micro Main Event on December 3, 2015
GlobeNewswire - Thu Nov 19, 6:05AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it will present at the 8 Annual LD Micro Main Event on December 3, 2015, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) at the Luxe Sunset Hotel in Los Angeles, CA.
Matinas BioPharma Reports 2015 Third Quarter Financial Results and Provides Business Update
GlobeNewswire - Tue Nov 10, 6:35AM CST
- Topline data from Phase 2a clinical trial with MAT2203, oral encochleated amphotericin B, expected in 2016 -
Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Encochleated siRNA
GlobeNewswire - Mon Oct 26, 7:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO"
for U.S. Patent Application Serial No. 14/038,810 entitled, "Cochleate Compositions Directed Against Expression of Proteins." Matinas BioPharma Selected to Present at Cavendish Global Health Impact Forum
GlobeNewswire - Thu Oct 22, 7:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it has been selected as a Cavendish Innovation Partner and will present at the Cavendish Global Health Impact Forum co-hosted by The Cleveland Clinic, which takes place October 25 to October 28 at The Cleveland Clinic, Cleveland, Ohio.
Matinas BioPharma to Present at the 14th Annual BIO Investor Forum on October 20, 2015
GlobeNewswire - Wed Oct 14, 6:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it will be presenting at the 14 Annual BIO Investor Forum being held October 20-21, 2015, at the Parc 55 in San Francisco, California.
Matinas BioPharma Presents Preclinical PK and Efficacy Data of Encochleated Atovaquone in Murine Model at IDWeek 2015
GlobeNewswire - Sat Oct 10, 7:00AM CDT
- CATQ - Encochleated Atovaquone - Demonstrates Enhanced Efficacy and Tissue Targeting over Current Formulation -
MarketExclusive.com - Maxim Group Reiterates BUY Rating for Matinas BioPharma Holdings, Inc. and Provides Company Update
ACCESSWIRE - Mon Oct 05, 1:04PM CDT
NEW YORK, NY / ACCESSWIRE / October 5, 2015 / Market Exclusive announces that Maxim Group has reiterated a Buy rating for Matinas BioPharma Holdings, Inc. (OTCQB:MTNB) with a 12-month price target of $6.00 per share. The analyst note was published following the announcement that Matinas has received IRB approval to commence a NIH-Sponsored Phase 2a study with MAT2203.
Matinas BioPharma Receives Institutional Review Board Approval to Commence NIH-Sponsored Phase 2a Study With MAT2203 - An Orally Delivered, Encochleated Formulation of Amphotericin B -
GlobeNewswire - Mon Oct 05, 6:00AM CDT
- NIH IRB Approves Study of MAT2203 - Oral, Encochleated Formulation of Amphotericin B -
Matinas BioPharma Presents Pre-clinical Data Showing Anti-bacterial Activity of MAT2501 - Encochleated Amikacin - Against Mycobacterium Avium Lung Infections at ICAAC/ICC 2015
GlobeNewswire - Sat Sep 19, 1:00PM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today presented preclinical data showing significant anti-bacterial activity against Mycobacterium avium (M. avium) and no noted toxicity by MAT2501, an orally-administered encochleated formulation of amikacin.
